PT  - JOURNAL ARTICLE
AU  - Krueger, Tyll
AU  - Gogolewski, Krzysztof
AU  - Bodych, Marcin
AU  - Gambin, Anna
AU  - Giordano, Giulia
AU  - Cuschieri, Sarah
AU  - Czypionka, Thomas
AU  - Perc, Matjaz
AU  - Petelos, Elena
AU  - Rosińska, Magdalena
AU  - Szczurek, Ewa
TI  - Risk of COVID-19 epidemic resurgence with the introduction of vaccination passes
AID  - 10.1101/2021.05.07.21256847
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.07.21256847
4099  - http://medrxiv.org/content/early/2021/05/14/2021.05.07.21256847.short
4100  - http://medrxiv.org/content/early/2021/05/14/2021.05.07.21256847.full
AB  - Many countries hit by the COVID-19 epidemic consider the introduction of vaccination passes. So far, no thorough impact assessment of vaccination passes and of lower restrictions for their holders has been conducted. Here, we propose the VAP-SIRS model that accounts for susceptible, infected, and recovered subpopulations, also within the group of vaccinated pass holders. The model accounts for imperfect vaccination effectiveness, revaccinations and waning immunity. Different restrictions for pass holders and the rest of the population result in different scenarios of the epidemic evolution, some of which yield unfavourable COVID-19 dynamics and new waves. We identify critical variables that should be considered by policymakers and show how unfavourable outcomes can be avoided using adaptive policies. In particular, while pass holders could initially be allowed large freedoms, the gradual loss of immunity will require either increased restrictions for pass holders, or accelerated revaccination. In the long-term, common restrictions for both the pass holders and the rest of the population will have to be kept to avoid epidemic resurgence. Such minimum required restrictions depend on vaccination effectiveness, revaccination rate, waning rate and fraction of never-vaccinated population, and, for realistic combinations of these parameters, range between 29% and 69% reduction of contacts.Competing Interest StatementOther projects in the research lab of ES are co-funded by Merck Healthcare KGaAFunding StatementTC has received funding from the European Union s Horizon 2020 research and innovation programme under grant agreement No 101016233 (PERISCOPE) GG acknowledges support by the University of Trento within the COVID-19 Strategic Project MOSES (Models for Reasoning about the Spreading of Diseases). MP was supported by the Slovenian Research Agency (Grant Nos. P1-0403 and J1-2457). EP acknowledges support by the University of Crete. ES acknowledges funding by the Polish National Science Centre OPUS grant no 2019/33/B/NZ2/00956 and SONATA-BIS grant no 2020/38/E/NZ2/00305Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable https://github.com/storaged/VAP-SIRS https://github.com/eMaerthin/Fig2_Fig3 http://bioputer.mimuw.edu.pl:85/VAP-SIRS/